Minimal Residual Disease in Neovascular Age-Related Macular Degeneration

Abstract

With the advent of long-acting anti-vascular endothelial growth factor substances, “healing of AMD (age-related macular degeneration)” might be easily assumed due to prolonged treatment intervals. Adoption of the oncological concept of minimal residual disease for quiescent choroidal neovascularization (CNV) lesions might enhance the importance of continued monitoring, and spur research into the core of the disease, i.e., CNV biology.

Zusammenfassung

Mit der Zulassung langwirksamer Anti-VEGF-Substanzen könnte in Zukunft der Eindruck beim Patienten entstehen, eine neovaskuläre altersbedingte Makuladegeneration sei „geheilt“, da lange Intervalle zwischen den einzelnen Behandlungen Realität geworden sind. Die Einführung des onkologischen Konzeptes „Minimal residual Disease“ (MRD) könnte hier die Bedeutung quiescenter, unter Behandlung nicht exsudativer choroidaler Neovaskularisationen wieder mehr in den Fokus rücken, um auf die Wichtigkeit des langfristigen Krankheitsmonitorings hinzuweisen.

Key words

minimal residual disease - complete remission - age-related macular degeneration - AMD - choroidal neovascularization - CNV

Schlüsselwörter

Minimal residual Disease - OCT - altersbedingte Makuladegeneration (Age-related macular Degeneration) - OCT

Publikationsverlauf

Eingereicht: 04. November 2020

Angenommen: 27. November 2020

Artikel online veröffentlicht:
14. April 2021

• References

• 1 Luskin MR, Murakami MA, Manalis SR. et al. Targeting minimal residual disease: a path to cure?. Nat Rev Cancer 2018; 18: 255-263 doi:10.1038/nrc.2017.125
• 2 Paietta E. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?. Bone Marrow Transplant 2002; 29: 459-465 doi:10.1038/sj.bmt.1703388
• 3 Stacey AW, Pulido JS. The Concept of Minimal Residual Disease in the Treatment and Staging of Vitreoretinal Lymphoma. Retina 2020; 40: 1213-1214 doi:10.1097/iae.0000000000002851
• 4 Gantner ML, Eade K, Wallace M. et al. Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. N Engl J Med 2019; 381: 1422-1433 doi:10.1056/NEJMoa1815111
• 5 Carnevali A, Cicinelli MV, Capuano V. et al. Optical Coherence Tomography Angiography: A Useful Tool for Diagnosis of Treatment-Naive Quiescent Choroidal Neovascularization. Am J Ophthalmol 2016; 169: 189-198 doi:10.1016/j.ajo.2016.06.042
• 6 Querques G, Srour M, Massamba N. et al. Functional characterization and multimodal imaging of treatment-naïve “quiescent” choroidal neovascularization. Invest Ophthalmol Vis Sci 2013; 54: 6886-6892 doi:10.1167/iovs.13-11665
• 7 Carnevali A, Sacconi R, Querques L. et al. Natural History of Treatment-Naïve Quiescent Choroidal Neovascularization in Age-Related Macular Degeneration Using OCT Angiography. Ophthalmol Retina 2018; 2: 922-930 doi:10.1016/j.oret.2018.02.002
• 8 Capuano V, Miere A, Querques L. et al. Treatment-Naive Quiescent Choroidal Neovascularization in Geographic Atrophy Secondary to Nonexudative Age-Related Macular Degeneration. Am J Ophthalmol 2017; 182: 45-55 doi:10.1016/j.ajo.2017.07.009
• 9 Nguyen V, Vaze A, Fraser-Bell S. et al. Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. Ophthalmol Retina 2019; 3: 623-628 doi:10.1016/j.oret.2019.05.013
• 10 Adrean SD, Chaili S, Grant S. et al. Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat-Extend-Stop Protocol. Ophthalmol Retina 2018; 2: 225-230 doi:10.1016/j.oret.2017.07.009
• 11 Arendt P, Yu S, Munk MR. et al. Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration. Retina 2019; 39: 27-33 doi:10.1097/iae.0000000000001923
• 12 Mahvi DA, Liu R, Grinstaff MW. et al. Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. CA Cancer J Clin 2018; 68: 488-505 doi:10.3322/caac.21498
• 13 Miere A, Semoun O, Cohen SY. et al. Optical coherence tomography angiography features of subretinal fibrosis in age-related macular degeneration. Retina 2015; 35: 2275-2284 doi:10.1097/iae.0000000000000819
• 14 Perrott-Reynolds R, Cann R, Cronbach N. et al. The diagnostic accuracy of OCT angiography in naive and treated neovascular age-related macular degeneration: a review. Eye (Lond) 2019; 33: 274-282 doi:10.1038/s41433-018-0229-6
• 15 Pfau M, Möller PT, Künzel SH. et al. Type 1 Choroidal Neovascularization Is Associated with Reduced Localized Progression of Atrophy in Age-Related Macular Degeneration. Ophthalmol Retina 2020; 4: 238-248 doi:10.1016/j.oret.2019.09.016